Brazil’s health regulator denies approval of Avifavir, Russian antiviral against Covid-19

Anvisa on Tuesday denied preliminary approval for the emergency use of the Russian drug Avifavir to treat patients with Covid-19.

RIO DE JANEIRO, BRAZIL - According to the vote of Director Meiruze Freitas, the drug does not meet the health regulator Anvisa's expectations in terms of minimum safety and efficacy requirements in the context of emergency use.

"You cannot approve the use of a drug that has not shown clinical benefit in the treatment of Covid-19 and yet can lead to health risks for patients," she said.

The drug, manufactured by Russian companies API - Technologies LLC and Joint Stock Company Chemical Diversity Research Institute - JSC CDRI, had registered the application for emergency use approval by the Vital Brazil Institute . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?